相关实验视频
Updated: Jan 12, 2026

Measurement of T Cell Alloreactivity Using Imaging Flow Cytometry
Published on: April 19, 2017
对NAT反应性和CLIA在检测输血传输感染中的血液捐献者的比较分析
Jyoti Kala Bharati1, Arvind Kumar Singh1, Yatendra Mohan1
1Department of Transfusion Medicine, Uttar Pradesh University of Medical Sciences, Saifai, Etawah, Uttar Pradesh-206130, India.
核酸检测 (NAT) 在血液捐献中为检测HIV,HBV和HCV提供了比化学发光免疫检测 (CLIA) 更高的灵敏度. 虽然这两种方法都有错误的阳性,但NAT识别了更多的感染,提高了血液安全.
科学领域:
- 输血医学 输血医学
- 传染病诊断 传染病诊断 传染病诊断
- 公共卫生 公共卫生
背景情况:
- 输血传染病 (TTIs) 对血液供应安全构成重大风险.
- 核酸检测 (NAT) 和化学发光免疫检测 (CLIA) 是TTIs的关键查方法.
- 评估NAT和CLIA的比较性能对于优化血液安全协议至关重要.
研究的目的:
- 为了比较NAT和CLIA在血液捐献中检测HIV,HBV和HCV的灵敏度,特异性和假阳性率.
- 与CLIA相比,评估NAT识别的感染的额外产量.
- 评估NAT与CLIA在TTI查中的成本效益.
主要方法:
- 对30335次献血的分析,重点是1843个反应单位.
- 对NAT和CLIA性能指标 (敏感性,特异性,假阳性率) 的比较评估.
- 通过NAT识别的额外感染病例的评估和成本效益分析.
主要成果:
- 与CLIA相比,NAT对HBV (98.50%),HIV (98%) 和HCV (97.50%) 的敏感性更高 (HBV: 79.09%,HIV: 94.44%,HCV: 64.20%).
- 这两种方法都显示出错误阳性率,CLIA-HCV达到70.6%.
- NAT发现了另外106例HBV和63例HCV病例,证明了HBV和HCV查的成本效益.
结论:
- NAT是一种高度敏感的TTI查工具,显著提高了血液安全性.
- CLIA需要进行确认测试,以减轻错误阳性并提高血液供应效率.
- 这些发现支持将NAT作为关键TTIs的主要选方法的整合.
更多相关视频
11:59Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
Published on: September 6, 2017
06:03Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
Published on: September 20, 2024
相关概念视频
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Blood Transfusion
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
Blood Typing
Antigens are protein molecules that reside on the surface of red blood cells (RBCs). The ABO and Rh blood typing systems target...